
Presented during the Late-Breaking Clinical Trials Session at #GlomConHawaii 🌺 @GlomCon Two-year VISIONARY results: Sibeprenlimab reduced proteinuria and preserved eGFR in IgA nephropathy, with consistent benefit across subgroups and a favorable safety profile.




















